1UO FDA Approval Status
FDA Approved: No
Brand name: 1UO
Generic name: uracil
Dosage form: Topical
Previous Name: Xyfid
Company: Cahaba Pharmaceuticals
Treatment for: Hand-Foot Syndrome
1UO (uracil) is a first-in-class dihydropyrimidine dehydrogenase (DPD) inhibitor in development for the treatment of Hand-Foot Syndrome (HFS), also known as Palmar-Plantar Erythrodysesthesia.
Development timeline for 1UO
|Sep 10, 2008||VioQuest Pharmaceuticals Receives 510(k) Response from FDA for Xyfid|
|Jul 1, 2008||VioQuest Pharmaceuticals Submits 510(k) Application to FDA for Xyfid, a Novel Topical Agent for the Treatment of Various Skin Disorders|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.